Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

简要总结

详细描述

主要结局

次要结局

• Number of patient eyes with Intraocular inflammation(12 and 6 months prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with the Provider specialty(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of patient eyes with the Last injection inetrval(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Time since any Age-related macular degeneration (AMD) diagnosis(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Age(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Gender information(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of patients at various Patient Region(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of patients with Laterality of wet Age-related macular degeneration (AMD)(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of eyes with the concurrent eye disease(Within 180 days prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patients with Laterality of any Age-related macular degeneration (AMD)(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of patient eyes with previous ocular surgeries or procedures(Within 180 days prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with prior Intraocular Inflammation (IOI) and/or prior Retinal vascular occlusion (RO)(12 months prior to the index date ( index date defined as the date of first brolucizumab injection))
• Number of patients with Insurance type(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Number of patient eyes with Systemic inflammation / auto-immune history (in total and at the event level)(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of eyes treated with brolucizumab(Index date defined as the date of the earliest brolucizumab injection during the index period (from 08-Oct-2019 to 30-Apr-2020))
• Time from last anti-VEGF injection to index date(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Number of ocular adverse events (AEs)(Post-index period defined as the 180 days following therapy initiation, excluding index date)
• History of other IOI and endophthalmitis due to infections or other underlying disease(36, 12 and 6 months prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with different prior anti-VEGF agents(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Time since wet Age-related macular degeneration (AMD) diagnosis(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with systemic comorbidities(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of Concomitant systemic medications (chronic use)(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with the Cataract status(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with the history of ocular inflammation (includes IOIs or panuveitis or endophthalmitis relevant to safety evaluation)(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with prior treatment status(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with prior anti-VEGF agents (total, per anti-VEGF agent)(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Number of patient eyes with Concomitant ocular medications(36-month period prior to the index date (inclusive of the index date) ( index date defined as the date of first brolucizumab injection))
• Type of exam performed(30 days before or on first brolucizumab injection (index date))
• Number of patient eyes with Anti-VEGF treatment-naive vs prior-treated(60 months prior to index ( index date defined as the date of first brolucizumab injection))
• Duration of last anti-VEGF treatment (total, per anti-VEGF agent)(60 months prior to index ( index date defined as the date of first brolucizumab injection))